Four RCTs, including 7087 patients with known coronary artery disease, ischemic stroke, or carotid artery plaque, were included in the analysis. Compared to placebo, tongxinluo numerically decreased the risk of stroke with a RR of 0.84 (95% CI: 0.61-1.17, p = 0.31). For the outcome of MACE, tongxinluo reduced the risk by 28% (RR: 0.72, 95% CI: 0.59-0.88, p = 0.001). Patients randomized to tongxinluo had a RR of 0.70 (95% CI: 0.54-0.92, p = 0.01) for cardiovascular mortality and 0.74 (95% CI: 0.56-0.92, p = 0.01) for all-cause mortality. In summary, in patients with ASCVD, tongxinluo tended to decrease the incidence of stroke, and reduced the composite of stroke, myocardial infarction, and cardiovascular mortality by 28%.
Feng et al. (Sun,) studied this question.